Jeil Pharmaceutical Co.,Ltd (KRX: 271980)

Jeil Pharmaceutical Co.,Ltd Statistics

Total Valuation

Jeil Pharmaceutical Co.,Ltd has a market cap or net worth of KRW 166.84 billion. The enterprise value is 220.66 billion.

Market Cap	166.84B
Enterprise Value	220.66B

Important Dates

The next estimated earnings date is Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Jeil Pharmaceutical Co.,Ltd has 14.57 million shares outstanding. The number of shares has increased by 0.00% in one year.

Current Share Class	n/a
Shares Outstanding	14.57M
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	13.15%
Owned by Institutions (%)	1.46%
Float	5.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.24
PB Ratio	0.99
P/TBV Ratio	1.02
P/FCF Ratio	14.48
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.16
EV / Sales	0.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	19.15

Financial Position

The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.42.

Current Ratio	1.09
Quick Ratio	0.69
Debt / Equity	0.42
Debt / EBITDA	n/a
Debt / FCF	6.62
Interest Coverage	-4.15

Financial Efficiency

Return on equity (ROE) is -21.80% and return on invested capital (ROIC) is -5.43%.

Return on Equity (ROE)	-21.80%
Return on Assets (ROA)	-2.83%
Return on Capital (ROIC)	-5.43%
Revenue Per Employee	697.64M
Profits Per Employee	-35.82M
Employee Count	1,000
Asset Turnover	1.40
Inventory Turnover	4.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.28% in the last 52 weeks. The beta is 1.12, so Jeil Pharmaceutical Co.,Ltd's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	-33.28%
50-Day Moving Average	12,991.60
200-Day Moving Average	15,157.35
Relative Strength Index (RSI)	42.19
Average Volume (20 Days)	12,902

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Jeil Pharmaceutical Co.,Ltd had revenue of KRW 697.64 billion and -35.82 billion in losses. Loss per share was -2,459.00.

Revenue	697.64B
Gross Profit	170.05B
Operating Income	-22.56B
Pretax Income	-38.02B
Net Income	-35.82B
EBITDA	-11.48B
EBIT	-22.56B
Loss Per Share	-2,459.00

Balance Sheet

The company has 37.58 billion in cash and 76.34 billion in debt, giving a net cash position of -38.76 billion or -2,660.07 per share.

Cash & Cash Equivalents	37.58B
Total Debt	76.34B
Net Cash	-38.76B
Net Cash Per Share	-2,660.07
Equity (Book Value)	183.75B
Book Value Per Share	11,577.20
Working Capital	27.76B

Cash Flow

In the last 12 months, operating cash flow was 16.15 billion and capital expenditures -4.62 billion, giving a free cash flow of 11.53 billion.

Operating Cash Flow	16.15B
Capital Expenditures	-4.62B
Free Cash Flow	11.53B
FCF Per Share	790.97

Margins

Gross margin is 24.38%, with operating and profit margins of -3.23% and -5.14%.

Gross Margin	24.38%
Operating Margin	-3.23%
Pretax Margin	-5.45%
Profit Margin	-5.14%
EBITDA Margin	-1.64%
EBIT Margin	-3.23%
FCF Margin	1.65%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.44%.

Dividend Per Share	50.00
Dividend Yield	0.44%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.00%
Shareholder Yield	0.44%
Earnings Yield	-21.48%
FCF Yield	6.91%

Stock Splits

The last stock split was on April 11, 2018. It was a forward split with a ratio of 1.4.

Last Split Date	Apr 11, 2018
Split Type	Forward
Split Ratio	1.4

Scores

Jeil Pharmaceutical Co.,Ltd has an Altman Z-Score of 1.64. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.64
Piotroski F-Score	n/a